Concurrent cisplatin-based chemoradiation for cervical carcinoma: Tumor response, toxicity, and serum cytokine profiles

Cancer Investigation

Volumn 24, Issue 4, 2006, Pages 390-395

  Yang, Yuh Cheng ^a,b   Wang, Kung Liahng ^a,c   Su, Tsung Hsien ^a,b   Liao, Hui Fen ^d   Wu, Meng Hao ^a   Chen, Tze Chien ^a   Huang, Ming Chao ^a   Chen, Yu Jen ^a,e  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b Mackay Medicine   (Taiwan)

^c NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

^d NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^e CHINESE CULTURE UNIVERSITY   (Taiwan)

Author keywords

Cervical cancer; Chemoradiation; G CSF; IL 6; TGF 1; VEGF

Indexed keywords

CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ADULT; ARTICLE; BIOCHEMISTRY; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; EVALUATION RESEARCH; FEMALE; HUMAN; MORBIDITY; NEUTROPHIL COUNT; PRIORITY JOURNAL; TUMOR VOLUME; UTERINE CERVIX CARCINOMA;

ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; CYTOKINES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-6; MIDDLE AGED; NEUTROPHILS; RADIOTHERAPY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33745291713     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900600705359     Document Type: Article

References (23)

1. Keys, H.M.; Bundy, B.N.; Stehman, F.B.; Muderspach, L.I.; Chafe, W.E.; et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. New Engl. J. Med. 1999, 340, 1154-1161.
2. Rose, P.G.; Bundy, B.N.; Watkins, E.B.; Thigpen, J.T.; Deppe, G.; et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. New Engl. J. Med. 1999, 340, 1144-1153.
3. Eifel, P.J.; Winter, K.; Morris, M.; Levenback, C.; Grigsby, P.W.; et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J. Clin. Oncol. 2004, 22, 872-880.
4. Comerci, J.T., Jr.; Runowicz, C.D.; Flanders, K.C.; De Victoria, C.; Fields, A.L.; Kadish, A.S.; Goldberg, G.L. Altered expression of transforming growth factor-beta 1 in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix. Cancer 1996, 77, 1107-1114.
5. Braun, L.; Durst, M.; Mikumo, R.; Crowley, A.; Robinson, M. Regulation of growth and gene expression in human papillomavirus-transformed keratinocytes by transforming growth factor-beta: implications for the control of papillomavirus infection. Mol. Carcinogen. 1992, 6, 100-111.
6. Vujaskovic, Z.; Groen, H.J. TGF-beta, radiation-induced pulmonary injury and lung cancer. Int. J. Radiat. Biol. 2000, 76, 511-516.
7. Li, C.; Wilson, P.B.; Levine, E.; Barber, J.; Stewart, A.L.; Kumar, S. TGF-beta1 levels in pre-treatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis. Int. J. Cancer 1999, 84, 155-159.
8. Dickson, J.; Davidson, S.E.; Hunter, R.D.; West, C.M. Pretreatment plasma TGF beta 1 levels are prognostic for survival but not morbidity following radiation therapy of carcinoma of the cervix. Int. J. Radiat. Oncol. 2000, 48, 991-995.
9. Jacobsen, S.E.; Ruscetti, F.W.; Dubois, C.M.; Lee, J.; Boone, T.C.; Keller, J.R. Transforming growth factor-beta trans-modulates the expression of colony stimulating factor receptors on murine hematopoietic progenitor cell lines. Blood 1991, 77, 1706-1716.
10. Gaugler, M.H.; Squiban, C.; Mouthon, M.A.; Gourmelon, P.; van der, M.A. Irradiation enhances the support of haemopoietic cell transmigration, proliferation and differentiation by endothelial cells. Brit. J. Haematol. 2001, 113, 940-950.
11. Chen, Y.M.; Whang-Peng, J.; Liu, J.M.; Wang, S.Y.; Tsai, C.M.; Perng, R.P. Elevation of serum interleukin-6 levels before peak of serum granulocyte colony-stimulating factor level in chemotherapy-induced myelosuppressive patients. J. Immunother. 1995, 17, 249-254.
12. Wei, L.H.; Kuo, M.L.; Chen, C.A.; Cheng, W.F.; Cheng, S.P.; Hsieh, F.J.; Hsieh, C.Y. Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecol. Oncol. 2001, 82, 49-56.
13. Srivani, R.; Nagarajan, B. A prognostic insight on in vivo expression of interleukin-6 in uterine cervical cancer. Int. J. Gynecol. Cancer 2003, 13, 331-339.
14. Tang, J.T.; Yamazaki, H.; Nishimoto, N.; Inoue, T.; Nose, T.; et al. Effect of radiotherapy on serum level of interleukin 6 in patients with cervical carcinoma. Anticancer Res. 1996, 16, 2005-2008.
15. Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 2002, 29, 15-18.
16. Gaffney, D.K.; Haslam, D.; Tsodikov, A.; Hammond, E.; Seaman, J.; et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int. J. Radiat. Oncol. 2003, 56, 922-928.
17. Lee, I.J.; Park, K.R.; Lee, K.K.; Song, J.S.; Lee, K.G.; et al. Prognostic value of vascular endothelial growth factor in Stage IB carcinoma of the uterine cervix. Int. J. Radiat. Oncol. 2002, 54, 768-779.
18. Bachtiary, B.; Selzer, E.; Knocke, T.H.; Potter, R.; Obermair, A. Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival. Cancer Lett. 2002, 179, 197-203.
19. Park, J.S.; Qiao, L.; Su, Z.Z.; Hinman, D.; Willoughby, K.; et al. Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways. Oncogene 2001, 20, 3266-3280.
20. Saito, S.; Kawano, Y.; Watanabe, T.; Okamoto, Y.; Abe, T.; Kurada, Y.; Takaue, Y. Serum granulocyte colony-stimulating factor kinetics in children receiving intense chemotherapy with or without stem cell support. J. Hematother. 1999, 8, 291-297.
21. Morstyn, G.; Campbell, L.; Souza, L.M.; Alton, N.K.; Keech, J.; et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988, 1, 667-672.
22. Morstyn, G.; Campbell, L.; Lieschke, G.; Layton, J.E.; Maher, D.; et al. Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J. Clin. Oncol. 1989, 7, 1554-1562.
23. Jacobsen, S.E.; Keller, J.R.; Ruscetti, F.W.; Kondaiah, P.; Roberts, A.B.; Falk, L.A. Bidirectional effects of transforming growth factor beta (TGF-beta) on colony-stimulating factor-induced human myelopoiesis in vitro: differential effects of distinct TGF-beta isoforms. Blood 1991, 78, 2239-2247.